Allergy-Immunology
Cardiology
Endocrinology
Gastroenterology
General Internal Medicine
Geriatric Medicine
Hematology / Oncology
Hepatology
Hospital Medicine
Immunotherapy
Infectious Diseases
Nephrology / Hypertension
Pulmonary & Critical Care
Rheumatology
Sports Medicine

Division of Cardiology

Bibliography 2003

2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |

Publications

  1. Adams KF, Mathur VS, Gheorghiade M. B type natriuretic peptide: from bench to bedside. Am Heart J 2003;145:S34-S46.

  2. Almeda FQ, Hendel RC, Macioch JE, Sandelski J, Parrillo JE, Meyer PM, Johnson M, Daniels ML, Go VU, Feinstein SB. Comparison of echocardiography using tissue harmonics and contrast harmonics with radionuclide angiography for the assessment of left ventricular function. J Invest Med 2003;51: 366-372.

  3. Amar D, Zhang H, Miodownik S, Kadish A. Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. J Am Coll Cardiol 2003:42:1262-1268.

  4. Balady GJ, O’Gara PT, Bonow RO. AHA Council on Clinical Cardiology: bringing the best science to the bedside for more than 50 years. Circulation 2003;107:1717-1718.

  5. Balcazar H, Bonow RO, Bradford WD, Buch J, Cefalu WT. Farquhar JW, Flack JM, Geersten R, Johnson PA, Houston Miller N, Libby P, Niaura RS, Pouleur H, Smith S Jr, Sorlie P, Spann SJ. Heart disease: an all-out attack on risk. Pfizer Journal 2003;7:4-49.

  6. Belch JJF, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton D, Gavin JR 3, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA. Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-892.

  7. Bello D, Farah GM, Di Luzio S, Shah D, Parker M, Johnson MR, Cotts WG, Klocke FJ, Bonow RO, Judd RM, Gheorghiade M, Kim RJ. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in heart failure patients undergoing beta-blocker therapy. Circulation 2003;108:1945-1953.

  8. Betts T, Goldberger J, Kadish A. Frequency and characterization of progressive aberrancy during supraventricular tachy-cardia. Am J Cardiol 2003;92:736-739.

  9. Bonow RO. The challenge of balancing scientific discovery and translation. Circulation 2003;107:358-362.

  10. Bonow RO, Eckel RH. Diet, obesity and cardiovascular risk. N Engl J Med 2003;348:2057-2058.

  11. Bonow RO. La difficile sfida del saper bialnciare la richerca scientifica con la sua diffusione. Cardiologia negli Ospedali 2003;113:12-20.
    12.

  12. Borer JS, Bonow RO. Contemporary approach to aortic and mitral regurgitation. Circulation 2003;108:2432-2438.

  13. Borrello F, Beahan M, Klein L, Gheorghiade M. Reappraisal of beta-blocker therapy in the acute and chronic post myocardial infarction period. Rev Cardiovasc Med 2003;4 (Suppl. 3):S13-S24.

  14. Burt R, Pearce W, Luo K, Oyama Y, Davidson C, Beohar N, Gheorghiade M. Hematopoietic stem cell transplantation for cardiac and peripheral vascular disease. Bone Marrow Transplant 2003;32 (Suppl 1): S29-S31.

  15. Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr., Dua V, Garringer J, Giri S, Caputo RP. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction Am J Cardiol 2003;92:977-980.

  16. Daviglus ML, Liu K, Yan LL, Pirzada A, Garside DB, Schiffer L, Dyer AR, Greenland P, Stamler J. Body mass index in middle age and health-related quality of life in older age: the Chicago Heart Association (CHA) detection project in industry study. Arch Intern Med 2003;163:2448-2455.

  17. Daviglus ML, Liu K, Pirzada A, Yan LL, Garside DB, Feinglass J, Guralnik JM, Greenland P, Stamler J. Relationship of favorable cardiovascular risk status in middle age to health-related quality of life in older age. Arch Intern Med 2003;163:2460-2468.

  18. Dei Cas L, Metra M, Nodari S, Dei Cas A, Gheorghiade M. Prevention and management of chronic heart failure in patients at risk. Am J Cardiol 2003;91:10F-17F.

  19. Eimer M, Rajamannan NM. Clinical Practice: Transient Ischemic Attack (letter) N Engl J Med 2003;348: 1606.

  20. Engelstein ED. Prevention and management of chronic heart failure: electrical therapy. Am J Cardiol 2003;91:62F-73F.

  21. Engelstein ED. Long QT Syndrome: a preventable cause of sudden death in women. Curr Women Health Rep 2003;3:126-134.

  22. Erodgan A, Davidson CJ. Recent clinical trials with iodixanol. Rev Cardiovasc Med 2003;4:S43-S49.

  23. Feinglass J, Martin GJ, Lin E, Johnson MR, Gheorghiade M. Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989-2000. Am Heart J 2003; 146:111-114.

  24. Felker MG, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, O’Connor CM. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003;92:625-628.

  25. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O’Connor CM. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.

  26. Felker GM, Adams KF, Konstam MA, O’Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003;145:S18-S27.

  27. Fintel DJ. The use of enoxaparin in emergency department protocols for early invasive approaches to managing chest pain patients. Invasive Cardiol Clinical Care Update 2003;5;1-3.

  28. Fonarow GC, Abraham WT, Cannon CP, Gheorghiade M, Sackner-Bernstein JD, Udelosn JE. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction: consensus guidelines. Rev Cardiovasc Med 2003;4 (Suppl. 3):S54-S59.

  29. François, CJ, Shors S, Bonow RO, Finn JP. Analysis of cardiopulmonary transit times at contrast material-enhanced MR imaging in patients with heart disease. Radiology 2003;227:447-452.

  30. Frigerio M, Oliva F, Turazza FM, Bonow RO. Prevention and management of chronic heart failure: the asymptomatic patient. Am J Cardiol 2003;91(9A):4-9.

  31. Gattis WA, Leimberger J, Felker MG, O’Connor CM, Gheorghiade M. Clinical Outcomes in patients on beta blocker therapy admitted with worsening chronic heart failure. Am J Card 2003;91:169-174.

  32. Gheorghiade M, Gattis WA, Lukas MA, O’Connor CM for the IMPACT-HF Investigators. Rationale and design of the Initiation Management Predischarge: process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. Am Heart J 2003;145:S60-S61.

  33. Gheorghiade M, Gattis WA, Barbagelata A, Adams K, Orlandi C, O’Connor CM, and for the ACTIV in CHF Investigators. Rationale and study design for a multicenter randomized double-blind placebo-controlled study of the effects of tolvaptan (OPC-41061) on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003;45:S51-S54.

  34. Gheorghiade M, Gattis WA, Adams KF, Jaffe AS, O’Connor CM, for the DUCCS Investigators. Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVD-HF). Am Heart J 2003;145:S55-S57.

  35. Gheorghiade M, Niazi I, Ouyang J, Czerwiece F, Kambayashi J, Zampino M, Orlandi C for the Tolvaptan Investigators. Vasopressin receptor blockade with tolvaptan in patients with congestive heart failure: Results of a double-blind randomized trial. Circulation 2003;107:2690-2696.

  36. Gheorghiade M, Colluci W, Swedberg C. Beta blockers in chronic heart failure. Circulation 2003;107: 1570-1576.

  37. Gheorghiade M, Davidson CJ. A comparison of arterial closure devices to manual compression in liver transplantation candidates undergoing coronary angiography. J Invasive Cardiol 2003;15:68-70.

  38. Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, O’Connor CM. Surrogate end points in heart failure trials. Am Heart J 2003;145:S67-S70.

  39. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF. Introduction. Am Heart J 2003;145:S1-S2.

  40. Gheorghiade M, GattisWA, Klein L. Time for change: rethinking the management of acute exacerbations of chronic heart failure. Eur J Heart Fail 2003;5:9-12.

  41. Goldberger J: Sustained atrial tachycardia in heart failure: is it the precursor to atrial fibrillation? J Cardiovasc Electrophysiol 2003;14:508-509.

  42. Greenland P. Improving risk of coronary heart disease. Can a picture make the difference? JAMA 2003;289:2270-2272.

  43. Greenland P, Gaziano JM. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 2003;349: 465-473.

  44. Greenland P, Deloria Knoll M, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as ante-cedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290: 891-897.

  45. Greenland P, Xie X, Liu K, Colangelo L, Liao Y, Daviglus ML, Agulnek AN, Stamler J. Prognostic importance of minor ST segment and/or T wave abnormalities in women and men: The Chicago Heart Association Detection Project in Industry (CHA) Study. Am J Cardiol 2003;91:1068-1074.

  46. Holly TA, Satran A, Bromet DS, Mieres JH, Frey MJ, Elliott MD, Heller GV, Hendel RC. Impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: results of the Both Exercise and Adenosine Stress Test (BEAST) Trial. J Nucl Cardiol 2003;10:291-296.

  47. Jain P, Massie B, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the acute exacerbation of chronic congestive heart failure resulting in hospitalization. Am Heart J 2003;145:S3-S17.

  48. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW for the STELLAR Study Group.* Am J Cardiol 2003;93;152-160. *Rosenson RS.

  49. Kadish A, Johnson D, Choe W, Robinson N, Goldberger J, Horvath G. Characterization of fibrillatory rhythms by ensemble vector directional analysis. Am J Physiol (Heart & Circulatory Physiology) 2003;285:H1705-1719.

  50. Kensey KR, Young C, Rosenson RS. Protective adaptation as an evolutionary response to mechanical injury in CVD. Today in Cardiology 2003;6:28.

  51. Klein L, Gheorghiade M. Therapeutic strategies for patients hospitalized with worsening heart failure. Editorial. Ital Heart J 2003;2:71-74.

  52. Klein L, O'Connor CM, Gattis WA, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003;91:18F-40F.

  53. Klocke FJ, Li D. Testing coronary flow reserve without a provocative stress - a “BOLD” approach. J Am Coll Card 2003;41:841-842.

  54. Klocke FJ, Baird MG, Bateman TM, Berman DS, Carabello BA, Cerqueira MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O’Gara PT, Russell RO, Jr., St. John Sutton MG, Udelson JE, Verani MS, Williams KA. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). Circulation 2003;108:1404-1418 J Am Coll Card 2003;42:1318-1333. Full text available at: http://www.acc.org/clinical/guidelines/radio/dirIndex.htm.

  55. Larsen JA. McPherson DD. Kadish AH. Goldberger JJ. Course of intra-atrial thrombi resolution using transesophageal echocardiography. Echocardiogr. 2003;20:121-128.

  56. Lee CR, Watkins ML, Patterson JH, Gattis WA, O’Connor CM, Gheorghiade M, Adams KF, Jr. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9-18.

  57. Lloyd-Jones DM, Wilson PWF, Larson MG, Leip EP, Beiser A, D’Agostino RB, Cleeman JI, Levy D. Lifetime risk for coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003; 163: 1966-1972.

  58. Lloyd-Jones DM, Camargo CA, Allen LA, Giugliano RP, O’Donnell CJ. Predictors of long-term mortality following hospitalization for primary unstable angina and non-ST-elevation myocardial infarction. Am J Cardiol 2003;92:1155-1159.

  59. MacDonald LA, Beohar N, Wang NC, Nee L, Chandwaney R, Ricciardi MJ, Benzuly KH, Meyers SN, O’Connor CM, Gattis WA, Adams KF, Shah MR, FreyA, Gheorghiade M for the RITZ 4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). Am Heart J 2003;145:S58-S60.

  60. MacDonald LA, Beohar N, Wang NC, Nee L, Chandwaney R, Ricciardi MJ, Benzuly KH, Meyers SN, Gheorghiade M, Davidson CJ. A comparison of arterial closure devices to manual compression in liver transplantation candidates undergoing coronary angiography. J Invasive Cardiol 2003;15: 68-70.

  61. MacDonald LA, Meyers S, Bennett CL, Fintel D, Grosshas N, Syegco R, Davidson CJ. Severe access site complications associated with low molecular weight heparin following cardiac catheterization. J Invasive Cardiol 2003;15:60-62.

  62. Maganti K, Rigolin VH. Stress echocardiography vs myocardial SPECT for risk stratification of patients with coronary artery disease. Current Opin Cardiol 2003;18:486-493.

  63. Mahrholdt H, Wagner A, Parker M, Regenfus M, Fieno DS, Bonow RO, Kim RJ, Judd RM. Relationship of contractile function to transmural extent of infarction in patients with chronic coronary artery disease. J Am Coll Cardiol 2003;42: 505-512

  64. Manson JE, Greenland P, LaCroix AZ. Exercise and the prevention of cardiovascular events in women [letter]. N Engl J Med 2003;348:79.

  65. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, Taylor L, Chan C, Sharma L, Schneider JR, Ridker PM, Green D, Quann M. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-761.

  66. McDermott MM, Greenland P, Liu K, Criqui MH, Guralnik JM, Celic L, Chan C. Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc 2003;51:222-228.

  67. McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, Greenland P. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157-2162.

  68. McDermott MM, Green D, Greenland P, Liu K, Criqui MH, Chan C, Guralnik JM, Pearce WH, Ridker PM, Taylor L, Rifai N, Schneider JR. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003;92:194-199.

  69. McDermott MM, Greenland P, Guralnik JM, Liu K, Criqui MH, Pearce WH, Chan C, Schneider J, Sharma L, Taylor LM, Arseven A, Quann M, Celic L. Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease. J Gen Intern Med 2003;18:461-467.

  70. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, Pearce WH, Taylor L, Ridker PM, Schneider JR, Martin G, Rifai N, Quann M, Fornage M. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003;107:3191-3198.

  71. Mieres JH, Shaw LJ, Hendel RC, Miller DD, Bonow RO, Berman DS, Heller GV. A report of the American Society of Nuclear Cardiology Task Force on Women and Heart Disease: Role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women. J Nucl Cardiol 2003;10:95-101.

  72. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Viramani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108:1664-1672.

  73. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-1778.

  74. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, MD, Semenkovich CF, Smith SC Jr, Young L, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003;108:2941-2948.

  75. O’Connor CM, Gattis WA, Adams KF, Hasselbad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M, for the RITZ-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous Tezosentan Study (RITZ-4). J Am Coll Cardiol 2003;41:1452-1457.

  76. O’Connor CM, Gattis WA, Teerlink JR, Adams KF, Gheorghiade M. Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. Am Heart J 2003;145:S47-S50.

  77. Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J 2003;4:232-235.

  78. Passman R, Horvath G, Thomas J, Kruse J, Shah A, Goldberger J, Kadish AH. Clinical spectrum and prevalence of neurologic events provoked by tilt table testing. Arch Intern Med 2003;163:1945-1948.

  79. Passman, R: Inappropriate ICD therapy in the short QT syndrome: old problem in a new disease. J Cardiovasc Electrophysiol 2003;14:1278-1279.

  80. Pasternak RC, Abrams J, Greenland P, Smaha LA, Wilson PWF, Houston-Miller N. 34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol 2003;41:1863-1874.

  81. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sallis JF Jr, Smith S Jr, Stone NJ, Taubert KA. American Heart Association Expert Panel on Population and Prevention Science. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003;107:645 - 651.

  82. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M for the EPHESUS Investigators (Gheorghiade M – Steering Committee). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.

  83. Prystkowsky EN, Niazi I, Curtis AB, Wilber DJ, Bahnson T, Ellenbogen K, Dahla A, Bloomfield DM, Gold M, Kadish A, Fogel RI, Gonzalez MD, Belardinelli L, Shreeniwas R, Wolff AA. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol 2003;42:1098-1102.

  84. Rajamannan NM, Edwards WD, Spelsberg TC. Histopathologic confirmation of hypercholesterolemic induced valvular heart disease. N Engl J Med 2003;349:717-718.

  85. Rajamannan NM, Gersh, B, Bonow RO. Calcific aortic stenosis: from bench to bedside. Heart 2003;89:1-5.

  86. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg TC. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-2184.

  87. Ricciardi MJ, Davidson CJ, Gubernikof G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145:522-528.

  88. Ricciardi MJ, Meyers S, Choi K, Pang JL, Goodreau L, Davidson CJ. Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events.Am Heart J 2003;146:507-512.

  89. Robbins JD, Maniar PB, Cotts W, Parker MA, Bonow RO, Gheorghiade M. Prevalence and severity of mitral regurgitation in chronic systolic heart failure. Am J Cardiol 2003;91:360-362.

  90. Rodin MB, Daviglus ML, Wong GC, Liu K, Garside DB, Greenland P, Stamler J. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age: the Chicago Heart Association Detection Project in Industry Study. Hypertension 2003; 42:61-68.

  91. Rosenson RS. Statin therapy: new therapy for cardiac microvascular dysfunction. Eur Heart J 2003;24:1993-1994.

  92. Rosenson RS, Bays HE. Results of 2 clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. Am J Cardiol 2003;91:878-881.

  93. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003;1:495-505.

  94. Rosenson RS. Preventive cardiology clinic: lpoprotein altering therapies to prevent cardiovascular disease in type 2 diabetes patients. Cardiol Rev 2003;20(Suppl):1-12.

  95. Rosenson RS. The biologic basis for ACE inhibitors in modulating atherosclerosis: how ACE inhibitors inhibit atherosclerosis. Clin Cardiol 2003;26:305-311.

  96. Rosenson RS, Koenig W. Clinical utility of inflammatory markers in the management of the coronary heart disease patient. Am J Cardiol 2003;92(suppl):10i-18i.

  97. Rosenson RS. Anti-atherothrombotic effects of nicotinic acid. Atherosclerosis 2003;171:87-96.

  98. Ruch S, Nishio M, Wasserstrom JA. Effect of cardiac glycosides on action potential characteristics and contractility in cat ventricular myocytes: Role of calcium overload. J Pharmacol Exp Ther 2003;307:419-428.

  99. Shors SM, Cotts WG, Pavlovic-Surjancev B, Fracois CJ, Gheorghiade M, Finn JP. Heart failure: evaluation of cardiopulmonary transit times with time resolved magnetic resonance angiography. Radiology 2003;229:742-784.

  100. Sjaastad I, Wasserstrom JA, Sejersted OM. Heart failure: a challenge to our concepts of EC-coupling. J Physiol (London) 2003;546:33-47.

  101. Stamler J, Elliott P, Appel L, Chan Q, Buzzard M, Dennis B, Dyer AR, Elmer P, Greenland P, Jones D, Kesteloot H, Kuller L, Labarthe D, Liu K, Moag-Stahlberg A, Nichaman M, Okayama A, Okuda N, Robertson C, Rodriguez B, Stevens M, Ueshima H, Van Horn L, Zhou B, for the INTERMAP Cooperative Research Group. Higher blood pressure in middle-aged American adults with less education role of multiple dietary factors: The INTERMAP Study. J Hum Hypertens 2003;17:655-664.

  102. Stone NJ, Kushner R. Effects of dietary modification to reduce vascular risks and treatment of obesity. Cardiol Clin 2003;21:415-433.

  103. Stone NJ. Are statins indicated for the primary prevention of coronary heart disease in octogenarians? Protagonist viewpoint. Am J Geriatr Cardiol 2003;12:351-356.

  104. Stone NJ. Hyperlipidemia and cardiovascular disease. Curr Opin Lipidol 2003;14:223-225.

  105. Thomas MJ, Sjaastad I, Andersen K, Helm PJ, Wasserstrom JA, Sejersted OM, Ottersen OP. Localization and function of the Na/Ca exchanger in normal and detubulated cardiomyocytes. J Mol Cell Cardiol 2003;35:1325-1337.

  106. Tiukinhoy S, Beohar N, Hsie M. Improvement in heart rate recovery following cardiac rehabilitation. J Cardiopulm Rehabil 2003;23:84-87.

  107. Vitarelli A, Tiukinhoy S, Di Luzio S, Zampino M, Gheorghiade M. The role of echocardiography in the diagnosis and management of heart failure. Heart Fail Rev 2003;8:181-189.

  108. Vlastos GA, Tangney CC, Rosenson RS. Effects of hydration on blood rheology. Clin Hemorheol Microcirc 2003;28:41-49.

  109. Wagh A, Stone NJ. Secondary causes of hypertriglyceridemia and pancreatitis. Clin Chim Acta 2003;332:21.

  110. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. The Lancet 2003;361:374-379.

  111. Wang S, Kensey K, Rosenson RS. Interindividual variability of whole blood viscosity improved with standardized hydration. Clinica Chimica Acta 2003;337:181-182.

  112. Wang S, Boss AH, Kensey KR, Rosenson RS. Variations of whole blood viscosity using rheolog™ – a new scanning capillary viscometer. Clinica Chimica Acta 2003;332:79-82.

  113. Wang TJ, Nam BH, D’Agostino RB, Wolf PA, Lloyd-Jones DM, Macrae CA, Wilson PW, Polak JF, O’Donnell CJ. Carotid intima-media thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation 2003; 108: 572-576.

  114. Zampino M, O’Connor CM, Gattis WA, Adams KF, Gheorghiade M. Concomitant use of positive inotropic agents to create a bridge to the successful initiation of beta - blocker therapy: a proposal for a trial. Am Heart J 2003;145:S62-S66.

Book Chapters

  1. Bonow RO. Assessment of myocardial viability. In: Sandler MP, Coleman RE, Wackers FJTh, Patton JA, Gottschalk A, eds. Diagnostic Nuclear Medicine, 4th Edition. Philadelphia: Lippincott Williams & Wilkins 2003:319-332.

  2. Bonow RO. Foreword. In: Jessup M and Loh E, eds. Heart Failure: A Clinician’s Guide to Ambulatory Diagnosis and Treatment. Totowa, NJ: Humana Press 2003:v-vi.

  3. Gheorghiade M, Bonow RO. Heart failure as a consequence of atherosclerotic coronary artery disease. In: Mann DL, ed. Heart Failure. A Companion to Braunwald’s Heart Disease Philadelphia: Elsiever Science 2003:351-362.

  4. Nahlawi M, Holly TA. Noncardiac surgery in the cardiac patient. In: Irwin RS, Rippe JM, eds. Intensive Care Medicine, 5th edition. Boston: Lippincott Williams & Wilkins, 2003:1652-1663.

  5. Rammohan C, Erdogan A, Davidson CJ. New Stent Technologies: coated, covered, and bifurcated stents. Controversies and Consensus in Imaging and Intervention. Choice Medical Communications 2003, 4-9.

  6. Rosenson RS. Lipid-lowering drugs and rheology. In: Gaw A, Shepherd J, eds. Lipids and Atherosclerosis Annual 2003 London: Martin Dunitz Limited. 2003, 19-35.

Symposia, Books

  1. de Luca I, Bonow RO, Gheorghiade M, Fedele F, eds. From Prevention to Management of Chronic Heart Failure. Am J Cardiol 2003:91(suppl 9F):1F-94F.

  2. Becker LC, Fintel DJ, Green D. Antithrombotic Therapy. 3rd Edition. Professional Communications, Inc., 2003.

  3. Bettman M, Alpert JS, Balke CW, Bonow RO, Chin MT, Costa F, Daniels SR, Fabumni R, Faxon D, Gardner TJ, Goff DC, Hong Y, Ingwall J, Patterson B, Robertson RM, Taubert K, Tiukinhoy SD, Watson K, Webb RC. American Heart Association Mentoring Handbook. Dallas: American Heart Association 2003.

Abstracts

  1. Adams KF, Patterson JH, Gattis WA, O’Connor CM, Schwartz TA, Gheorghiade M. Favorable effects of digoxin on mortality and morbidity in patients with class IV CHF due to systolic dysfunction – retrospective analysis of the DIG study. J Am Coll Cardiol 2003;41:164A.

  2. Bello D, Fieno D, Pereles S, Song G, Wesson A, Passman R, Kadish A, Goldberger J. Infarct morphology identifies patients with substrate for ventricular tachycardia. J Am Coll Cardiol 2003;41:86A.

  3. Chandler AB, O’Connor CM, Gattis WA, Gallup DS, Fath K, Hettleman B, Gheorghiade M. Ppatients with preserved systolic function hospitalized for decompensated heart failure have 60-day event rates similar to patients with systolic dysfunction: observations from the IMPACT-HF Registry. J Card Fail 2003;9:S12.

  4. Coussios C-C, Holland CK, Jakubowska L, Huang SL, MacDonald RC, Nagaraj A, McPherson DD. Acoustic characterization of liposome suspensions and Optison at 3.5 MHz. J Acoust Soc Am 2003; 113.

  5. Daviglus ML, Liu K, Yan LL, Pirzada A, Garside DB, Dyer AR, Greenland P, Stamler J. Relationship of cigarette smoking in middle age and quality of life in later life: the Chicago Heart Association Detection Project in Industry. Circulation 2003;107:e7001.

  6. Daviglus ML, Liu K, Yan LL, Garside DB, Greenland P, Manheim, Dyer AR, Wang R, Pirzada A, Stamler J. Does cardiovascular risk status at younger age influence Medicare health care costs in the last year of life? Circulation 2993;108:IV-741.

  7. Daviglus ML, Greenland P, Stamler J, Elliott P, Kesteloot H, Claeys G, Appel LJ, Chan Q, Miura K, Steffen L, Nakagawa H, Zhou B, Pirzada A, Carnethon M, Dyer AR for the INTERMAP Research Group. Relation of blood pressure, dietary and other lifestyle factors to microalbuminuria in non-diabetic men and women ages 40-59: the INTERMAP Study. Circulation 2993;108:IV-764.

  8. Decker RS, Nakamura S, Decker M, Harris K, Winegrad S, Klocke FJ. Protein-protein interactions between myosin and titin are weakened by the dephosphorylation of myosin binding protein-C (MyBP-C) during low-flow ischemia. Circulation 2003;108:IV-125.

  9. Eimer MJ, Ekery D, Rigolin V, Bonow RO, Cotts W. Serum B-type natriuretic peptide in patients with chronic mitral regurgitation is not elevated. J Am Col Cardiol 2003:41;509A.

  10. Fonarow GC, Bonow RO, Tyler P, Hong Y, Skea W, Emond JA, Smith SC, LaBresh KA. Does the AHA Get With the Guidelines Program improve the quality of care in hospitalized patients with coronary artery disease at both teaching and non-teaching hospitals? Circulation 2003;108:IV-721.

  11. Gattis WA, O'Connor CM, Gallup DS, Chandler AB, Chu AA, Gheorghiade M. Predictors of 60-day death or rehospital-ization in patients admitted with decompensated heart failure: insights from the IMPACT-HF Trial and Registry. Circulation 2003;108:IV-694.

  12. Ghali JK, Adams KF Jr, Mehra MR, Pina IL, Wagoner LE, Oren RM, Sueta CA, Dunlap SH, Gheorghiade M, Cotts WG, Gattis WA, George S, Patterson JH. “Impaired Renal Function is Common in Outpatients with Heart Failure: Results from the STAMINA-HFP (Study of Anemia in Heart Failure Popul-ation) Registry. J Card Fail 2003;9:S75.

  13. Gheorghiade M, Gattis WA, Gallup DS, Chandler AB, Chu AA, Hasselbad V, O’Connor CM. Pre-discharge initiation of carvedilol in patients stabilized during an admission for decompensated heart failure is a safe and effective strategy to improve the use of beta-blocker therapy: results of the IMPACT-HF Trial. J Card Fail 2003;9:S59.

  14. Gheorghiade M, Gattis WA, Adams KF Jr, Jaffe AS, O’Connor CM. A Prospective Randomized Study of Nesiritide Versus Dobutamine in Decompensated Heart Failure (PRESERVD-HF): design and preliminary data. J Card Fail 2003;9:S63.

  15. Gheorghiade M, Gattis WA, Gallup DS, Chandler AB, Chu AA, Hasselblad V, O'Connor CM. Pre-discharge initiation of carvedilol in patients stabilized during an admission for decompensated heart failure is a safe and effective strategy to improve the use of beta-blocker therapy: results of the IMPACT-HF Trial. Circulation 2003;108:IV-668

  16. Gidea C, Goldberger J. Asymptomatic bradycardia is a risk factor for symptomatic bradycardia. Pacing Cardiac Electrophysiol 2003;26:1102.

  17. Greenland P, Liu K, Daviglus ML, Nelson JC, Psaty B, Schreiner P, Olson J, Burke G. Favorable risk factor profile ("low risk") is associated with less subclinical atherosclerosis: The MESA Study. Presented at the 43rd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 5-8, 2003, Miami, FL. Circulation 2003;107:e7001.

  18. Hamilton AJ, Huang SL, Rabbat M, Warnick D, Nagaraj A, Kane BJ, Klegerman M, MacDonald RC, McPherson DD. Intravascular ultrasound molecular imaging of ICAM-1, VCAM-1, fibrinogen, and fibrin in a Yucatan miniswine model of atherosclerosis. J Am Coll Cardiol 2003;41:300A.

  19. Harrison JK, Hermiller JB, Vetrovec GW, Smith JE, Pulsipher MW, Kern MJ, Conn EH, Navetta FI, She L, Pieper K, Sketch MH, Tcheng JE, Davidson CJ. A randomized study of 1276 patients undergoing PCI using iodixanol (Visipaque) vs iopamidol (Isovue): comparison of in hospital and 30 day major adverse cardiac events. The results of the VICC Trial. Circulation 2003;108:IV-354.

  20. Holland CK, Coussios C-C, Jakubowska L, Huang S, MacDonald RC, Nagaraj A, McPherson DD. In vitro characterization of liposomes and Optison by acoustic scattering at 3.5 MHz. J Ultrasound Med 2003;29:S213.

  21. Huang S-L, Tiukinhoy S, Wang L, Nagaraj A, McPherson D, MacDonald R. Acoustically-active liposomes of novel cationic-anionic composition in conjunction with ultrasound for gene delivery into vascular smooth muscle cells. Molecular Therapy 2003;7:S167.

  22. Kaneda H, Buchbinder M, Nakamura M, Popma JJ, Whitlow PL, Rogers CD, Vardi G, Davidson CJ, Moses JW, Fitzgerald PJ. Angiographic outcomes of a novel stent and delivery system for the treatment of bifurcation lesions. Am Heart J 2003;92:212L.

  23. Kean AJ, Seghatol FF, Ewert GD, Mehlman DJ, McPherson DD, Rigolin VH. Assessment of left ventricular diastolic function following completion of a marathon in a group of well trained runners. J Am Coll Cardiol 2003:41;199A

  24. Kim HW, Shah DJ, Patel MR, Kandzari D, Hayes B, Heitner JF, Parker M, Klocke FJ, Judd RM, Kim RJ. Contrast MRI detects myocardial viability in patients with chronic total occlusions. Circulation 2003;108:IV-698.

  25. Klein L, Gattis WA, Leimberger JD, Piña IL, O’Connor CM, Gheorghiade M. Prognostic Value of Hyponatremia in hospitalized patients with worsening heart failure: insights from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME - CHF). Eur Heart J 2003;24:P432.

  26. Klein L, Gattis WA, Leimberger JD, Piña IL, O’Connor CM, Gheorghiade M. Prognostic value of hyponatremia in hospitalized patients with worsening heart failure: insights from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME - CHF). J Card Fail 2003;9:S83.

  27. LaBresh KA, Fonarow GC, Ellrodt G, Bonow RO, Smaha LA, Tyler PA, Skea W, Hong Y, Emond J, Smith SC. Get With the Guidelines improves cardiovascular care in hospitalized patients with CAD. Circulation 2003;108:IV-722.

  28. Lee CR, Patterson JH, Gattis WA, Ghali JK, Shah PJ, Schwartz TA, Gheorghiade M, Adams FA. Renal dysfunction is common in patients with heart failure and preserved systolic function: retrospective analysis of the Digitalis Investigational Group (DIG). Circulation 2003;108:IV-484.

  29. Liu K, Daviglus ML, Yan LL, Garside DB, Greenland P, Manheim, Dyer AR, Stamler J. Cardiovascular disease (CVD) risk factor status earlier in adulthood and cumulative health care costs from age 65 to the point of death. Circulation 2993;108:IV-722.

  30. Macioch JE, Patel S, Bai C, Bhatt P, Meyer P, Geohas C, Davidson ME, Provost JC, Feinstein SB. Contrast enhanced ultrasound imaging measurement of carotid artery intimal medial thickening. J Am Coll Cardiol 2003;41:318A.

  31. Maganti K, Shakir N, Smulevitz B, Kane BJ, Nagaraj A, Fullerton DA, Bonow RO, McPherson DD. Left ventricular remodeling differs in chronic aortic insufficiency and mitral regurgitation following surgical correction. J Am Coll Cardiol 2003:41;502A.

  32. Maganti K, Smulevitz B, Kane BJ, Adelye A, Nagaraj A, Fullerton DA, Bonow RO, McPherson DD, Rigolin VH. Early and late changes in left ventricular morphology following mitral valve repair for chronic mitral regurgitation. J Am Soc Echocardiogr 2003;16:503.

  33. Margolis KL, Assaf AR, Bray PF, Greenland P, Grimm RH Jr, Howard BV, Manson JE, Rodabough R. Leukocyte count as a predictor of cardiovascular events in black and white post-menopausal women. Presented at the 43rd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 5-8, 2003, Miami, FL. Circulation 2003;107:e7001.

  34. McDermott MM, Tiukinhoy SD, Gluckman TJ, Unterreiner SC, Liu K, Greenland P, Criqui MH, Guralnik JM. The effects of exercise on lower extremity functioning in peripheral arterial disease patients without intermittent claudication: A randomized controlled clinical trial. J Am Coll Cardiol 2003; 41:304A.

  35. Moses JW, Kereisakes D, Williams DO, Douglas J, Lambert C, Simonton C, Cleman M, Davidson C, Vellinga T, Leon MB. Should sirolimus-eluting stents be the new standard for LAD therapy? A SIRIUS substudy. J Am Coll Cardiol 2003; 41:73A.

  36. Mozes MF, Mullen GM, Johnson MR, Jacobs WR, McPherson DD, Harmon K, Malinowska K. Observations on the use of 2-D echocardiograms in evaluating cadaver donor hearts. Am J Transplantation 2003;5:528.

  37. O'Connor CM, Gattis WA, Gallup DS, Hasselblad V, Gheorghiade M. A prospective registry of patients hospitalized for worsening heart failure: observations from the IMPACT-HF registry. Eur Heart J 2003;24:P1022.

  38. O’Connor CM, Gattis WA, Gallup DS, Agocha A, Brown CS, Browne KF, Gheorghiade M. Clinical characteristics, treatment patterns, and 60-day outcomes of patients hospitalized for worsening heart failure: Insights from the IMPACT-HF Registry. J Card Fail 2003;9:S72.

  39. O'Connor CM, Gattis WA, Hasselblad V, Kobrin I, Adams KF, Gheorghiade M. Elevated troponin I predicts clinical events in patients admitted with acute heart failure: insights from the RITZ-4 Trial. J Am Coll Cardiol 2003;41:142A.

  40. Passman R, Shah A, Kimmel S. Development and validation of a prediction rule for post-CABG atrial fibrillation. Pacing Clin Electrophysiol, 2003;26:399.

  41. Pavlovic-Surjancev B, Shors SM, Cotts WG, Pereles S, Carr J, Johnson MR, Gheorghiade M, Bonow RO, Finn JP. Magnetic resonance imaging provides accurate noninvasive hemodynamic assessment in heart failure: correlation with invasive hemodynamic measurements. J Card Fail 2003;9S: S93.

  42. Pitt B, Zannad F, Bittman, Staten M, Anderson J, Gheorghiade M, van Veldhuisen DJ, Kleiman JH. The EPHESUS Trial: evaluation of eplerenone in the subgroup of patients with baseline left ventricular ejection fraction ≤ 30%. J Card Fail 2003;9:S57.

  43. Quigg R, Goldberger J, Schaechter A, Levine J, Kadish A. Gender differences in patients with non-ischemic cardiomyopathy enrolled in the Defibrillators in Non-Ischemic Cardiomyopathy Trial (DEFINITE). J Card Fail 2003:9:S75.

  44. Rajamannan NM, Smith T, Nee L, Sebo TJ, Khan R, Bonow RH, Fredericksen J, Fullerton DA, Tajik AJ, Bonow RO. Calcified rheumatic heart valves are associated with osteopontin bone matrix expression. J Am Coll Cardiol 2003; 41:500A.

  45. Rajamannan NM, Subramanium M, Springett M, Niekrasz MA, Stock S, Ignatiev K, McConnell J, Singh R, Stone N, Bonow RO, Spelsberg TC. Atorvastatin inhibits aortic valve calcfication in an experimental model of chronic hypercholesterolemia via nonlipid lowering effects. J Am Coll Cardiol 2003;41:507A.

  46. Rajamannan NM, Subramanium M, Bhattacharyya RS, Spelsberg TC, Stern PH, Atorvastatin inhibits hyper-cholesterolemia activation of cell-cell interactions in the aortic valve to induce cellular proliferation and bone matrix production. J Bone Mineral Res 2003;18:S108.

  47. Rajamannan NM, Subramanium M, Springett M, Stock S, McConnell J, Singh R, Bonow RO, Spelsberg TC. Atorvastatin inhibits LRP5-mediated ectopic bone formation in the aortic valves of hyperlipidemic rabbits. Circulation 2003;108:IV-300.

  48. Rosenson RS. Efficacy and Safety of Pravastatin 80 mg and 160 mg. J Am Coll Cardiol 2003;41:228A.

  49. Rosenson RS, Tangney CC, Parker T, Levine D, Gordon B. Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. J Am Coll Cardiol 2003;41:290A.

  50. Russo RJ, Wong SC, Marchant D, Attubato MJ, Koor K, Davidson CJ, Tuzcu EM, Feldman T, Ling FS, Silva PD. Intravascular ultrasound-directed clinical decision making in the setting of an inconclusive left main coronary angiogram: final results from the Left Main IVUS Registry. Circulation 2003:108;IV-462.

  51. Seghatol FF, Shah DJ, DiLuzio S, Bello D, Johnson MR, Cotts WG, O’Donohue JA, Bonow RO, Gheorghiade M, Rigolin VH. The value of dobutamine stress echo in predicting improvement in left ventricular function in patients with ischemic and nonischemic cardiomyopathy after one year of beta-blocker therapy. J Am Coll Cardiol 2003; 41:164A.

  52. Shah DJ, Kim HW, Elliott M, Wu E, Thomson LE, Klem I, Parker MA, Bonow RO, Judd RM, Kim RJ. Contrast MRI predicts reverse remodeling and contractile improvement in akinetic thinned myocardium. Circulation 2003;108:IV-697.

  53. Shah PJ, Patterson JH, Gattis WA, Ghali JK, Lee CR, O’Connor CM, Schwartz TA, Gheorghiade M, Adams KF Jr. Risk of death in patients with preserved systolic function: retrospective analysis of the Digitalis Investigational Group (DIG) Trial. J Card Fail 2003;9:S85.

  54. Tiukinhoy S, Gluckman T, Weinberg K, Jain P, Bello D, Kadish A, Goldberger J. Autonomic effects on heart rate recovery in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:167A.

  55. Tiukinhoy SD, Gluckman T, Unterreiner S, Greenland P, McDermott MM. Chronotropic response to exercise in patients with peripheral arterial disease without classical symptoms of intermittent claudication. J Am Coll Cardiol 2003;41:252A.

  56. Weinberg KM, Tiukinhoy SD, Jain P, Kadish AH, Goldberger JG. Effect of cardiac rehabilitation on autonomic tone in patients with coronary artery disease. Circulation 2003;108: IV-759.

  57. Wu FI, Nagaraj A, FildesJM, Davidson CJ, Mockros LF, McPherson DD. Vascular acoustic emission parameters better identify and characterize angioplasty-induced injury. J Am Coll Cardiol 2003;41:2A.

  58. Yan LL, Daviglus ML, Liu K, Garside DB, Stamler J, Greenland P. Favorable cardiovascular risk status in middle age and Medicare diagnoses of coronary heart disease, stroke, cardiovascular diseases and diabetes mellitus in older age. Circulation 2003;107:e7001.

  59. Yan LL, Liu K, Daviglus ML, Kiefe CI, Sidney S, Matthews KA, Greenland P. Educational Attainment and coronary artery calcium. Circulation 2993;108:IV-755.

  60. Zhang H, Miodownik S, Kadish A. Autonomic changes preceding the onset of postoperative atrial fibrillation. J Am Coll Cardiol 2003;41:101A.

CD-Roms

  1. Braun LT, Rosenson RS. Effects of exercise on lipoproteins and hemostatic factors. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  2. Rosenson RS. Primary disorders of LDL-cholesterol metabolism. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  3. Rosenson RS. Secondary causes of dyslipidemia. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  4. Rosenson RS. Approach to the patient with hypertriglyceridemia. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  5. Rosenson RS. Cholesterol-lowering after acute myocardial infarction. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  6. Rosenson RS. Clinical trials of cholesterol lowering for primary prevention of coronary heart disease. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  7. Rosenson RS. Clinical trials of cholesterol lowering in patients with coronary heart disease. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  8. Rosenson RS, Tangney CC. Lipid lowering with drugs other than statins and fibrates. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  9. Rosenson RS. Lipid lowering with fibric acid derivatives. In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  10. Rosenson RS. Lipid lowering with HMG CoA reductase inhibitors (statins). In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  11. Rosenson RS. Mechanisms of benefit of lipid lowering in patients with coronary heart disease In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  12. Rosenson RS. Treatment guidelines for hypercholesterolemia In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  13. Rosenson RS. Treatment of dyslipidemias in the elderly In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  14. Rosenson RS, Reeder GS, Kennedy HL. Beta blockers in acute myocardial infarction In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  15. Rosenson RS, Kang DS. Overview of homocysteine In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  16. Tangney CC, Rosenson RS. Cardiovascular benefits and risks of moderate alcohol consumption In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  17. Tangney CC, Rosenson RS. Antioxidants in coronary heart disease In: Rose B, ed. UpToDate. BDR, Inc., Wellesley, MA 02181. 2003; Vol. 11.2.

  18. Rosenson RS. High dose pravastatin – safe, benefical? J Cardiovasc Med 2003;9. CD-ROM.